Long-Term Survival After Venous Thromboembolism: A Prospective Cohort Study. by Nilius, Henning et al.
ORIGINAL RESEARCH
published: 01 October 2021
doi: 10.3389/fcvm.2021.749342
Frontiers in Cardiovascular Medicine | www.frontiersin.org 1 October 2021 | Volume 8 | Article 749342
Edited by:
Colin E. Evans,
Northwestern University, United States
Reviewed by:
Håkan Wallen,







This article was submitted to
Thrombosis,
a section of the journal
Frontiers in Cardiovascular Medicine
Received: 29 July 2021
Accepted: 08 September 2021
Published: 01 October 2021
Citation:
Nilius H, Mertins T, Boss R,
Knuchel M, Blozik E, Kremer
Hovinga JA, Eichinger S and Nagler M
(2021) Long-Term Survival After
Venous Thromboembolism: A
Prospective Cohort Study.
Front. Cardiovasc. Med. 8:749342.
doi: 10.3389/fcvm.2021.749342
Long-Term Survival After Venous
Thromboembolism: A Prospective
Cohort Study
Henning Nilius 1,2, Tamara Mertins 1, Robin Boss 1, Matthias Knuchel 1, Eva Blozik 3,
Johanna Anna Kremer Hovinga 4, Sabine Eichinger 5 and Michael Nagler 1,4*
1University Institute of Clinical Chemistry, Inselspital University Hospital, University of Bern, Bern, Switzerland, 2Department of
Epidemiology, Maastricht University, Maastricht, Netherlands, 3Department of Health Sciences, Helsana Group, Zuerich,
Switzerland, 4Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, and
University of Bern, Bern, Switzerland, 5Department of Medicine 1, Medical University of Vienna, Vienna, Austria
Background: Little is known about long-term survival after the initial treatment of venous
thromboembolism (VTE). In a prospective cohort study, we aimed to assess the long-term
mortality and key predictor variables relating to disease severity, treatment intensity,
and comorbidities.
Materials and Methods: Between 1988 and 2018, 6,243 consecutive patients
with VTE from a University outpatient unit were prospectively included and followed
until December 2019; clinical characteristics, measures of disease severity, and
treatment details were recorded. Dates of death were retrieved from the Swiss Central
Compensation Office.
Results: Overall, 254 deaths occurred over an observation period of 57,212
patient-years. Compared to the Swiss population, the standardized mortality ratio was
1.30 (95% CI: 1.14, 1.47; overall mortality rate: 4.44 per 1,000 patient-years). The
following predictors were associated with increased mortality: Unprovoked VTE (hazard
ratio [HR]: 5.06; 95% CI: 3.29, 7.77), transient triggering risk factors (HR: 3.46; 95%
CI: 2.18, 5.48), previous VTE (HR: 2.05; 95% CI: 1.60, 2.62), pulmonary embolism
(HR: 1.45, 95% CI: 1.10, 1.89), permanent anticoagulant treatment (HR: 3.14; 95% CI:
2.40, 4.12), prolonged anticoagulant treatment (7–24 months; HR: 1.70; 95% CI: 1.16,
2.48), and cardiovascular comorbidities. Unprovoked VTE, previous VTE, permanent and
prolonged anticoagulation remain independent risk factors after adjustment for age, sex,
and comorbidities.
Conclusion: Survival after VTE was significantly reduced compared to the Swiss general
population, especially in patients with more severe disease, cardiovascular comorbidities,
and longer anticoagulant treatment.
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INTRODUCTION
Venous thromboembolism (VTE) is a common vascular disorder
that contributes significantly to the global disease burden (1). The
incidence of VTE is estimated to be 80–270 per 100,000 persons
with a short term mortality rate comparable to ischemic stroke
(2–4). A significant proportion of patients dies in the acute phase
due to heart failure following pulmonary embolism (PE) (5). In
patients who survive the acute phase of the disease, the mortality
rate is often perceived as low.
To date, knowledge about long-term mortality and its
predictors is limited, and previous studies’ results are conflicting.
Various analyses using data from the Dutch MEGA study (6), the
US Olmsted county cohort (7), the Swiss SWITCO65+ cohort
(8), and cohorts from Australia (9), and Italy (10, 11) identified
malignancy as the most important risk factor for mortality.
Advanced age, male sex, and cardiovascular comorbidities were
reported as major risk factors in an analysis of the Taiwanese
National Health Insurance database (12), the SWITCO65+
cohort (8), and the Olmsted county cohort (7). In contrast,
unprovoked VTE was a major risk factor for mortality in the
TEHS cohort (13), and in a Norwegian cohort (14). Of note, long-
term heparin treatment was observed as a risk factor in the Italian
MASTER registry (11). Interpretation of previous studies is,
however, difficult because of various methodological limitations.
Either, a retrospective or case-control design was used, a small
range of variables reflecting disease severity, treatment intensity,
and comorbidities was recorded, the sample size was small, or
the observation time was short. The question arises, whether
the long-term survival of VTE patients is indeed low, and
which factors contribute to mortality. Do comorbidities solely
determine the mortality, or do disease severity and treatment
intensity play a role?
Aiming to comprehensively assess the effect of disease
severity, treatment intensity, and comorbidities on the long-term
survival of patients with VTE, we conducted a large, prospective
cohort study with patient follow-up for up to 30 years and
recorded a broad set of predictor variables.
MATERIALS AND METHODS
Study Design, Setting, and Population
SeProV (“Secondary prophylaxis of venous thromboembolism
in the Greater Bern Area”) is a long-term prospective cohort
study conducted in Bern, Switzerland. Between 1988 and 2018,
all consecutive patients, which were referred for VTE risk
assessment to a specialized outpatient unit at the Inselspital, Bern
University Hospital, were included and followed until December
2019. Patients were usually referred following (a) venous
thromboembolism, (b) arterial thromboembolism, (c) or positive
family history (Figure 1). We expect that the majority of patients
with VTE have been referred to our center. Out of this cohort,
the following inclusion criteria were applied: (1) objectively
confirmed VTE [venography or duplex sonography in case of
deep vein thrombosis (DVT), spiral computed tomography,
ventilation-perfusion scan or pulmonary angiography in case of
PE, and various techniques in case of rare VTE], (2) referral
for VTE risk assessment, and (3) age above 18 years. Exclusion
criteria were (a) refused informed consent, and (b) active cancer.
The Inselspital is one of the largest academic hospitals in
Switzerland and has a catchment population of ∼2 million
inhabitants. A formal risk assessment is recommended in all
patients considered for secondary prophylaxis of VTE and the
specialized outpatient unit of the Inselspital is themost important
center for risk assessment in the greater Bern area. We, therefore,
expect that the majority of patients with VTE have been referred
to our center. This study was approved by the ethical committee
(Kantonale Ethikkommission Bern; #18-00389) and informed
consent was obtained from all participants. The study was
conducted in accordance with the Declaration of Helsinki.
Data Collection
Patients were screened and included during VTE risk assessment
in a specialized outpatient unit. In our setting, VTE risk
assessment is recommended after completion of initial
anticoagulant treatment following VTE. Clinical characteristics
were prospectively recorded in a structured assessment form
by the responsible resident and then reviewed by the attending
physician. The consistency of data was additionally checked by
a trained study nurse and a trained investigator. Parameters
of interest and corresponding values were defined beforehand,
and the definitions were included in the data collection forms.
The following data were obtained: age, sex, type of index
VTE, presence of triggering risk factors, presence of previous
VTE, family history of VTE, presence of arterial thrombosis,
smoking status, obesity, presence of systemic diseases including
inflammatory bowel disease and systemic lupus erythematodes,
diabetes, coronary heart disease without myocardial infarction,
chronic lung disease, hypertension, active cancer, chronic kidney
disease, and anemia. Treatment details including duration of
anticoagulation were additionally recorded. By matching the
patients with the Unique Person Identification registry of the
Central Compensation Office (ZAS) which provides complete
death data of all Swiss residents, the vital status, and time point
of death were acquired. All Swiss civil registries automatically
report to this database, and it is regarded as complete. The
matching was based on a national social insurance number (SV
number) of Swiss residents, which is unique, anonymous, and
not based on personal characteristics. Patients that were not
found in the registry, e.g., due to migration to another country,
were censored at the time of the last visit at the Inselspital Bern.
Definition of Variables
Death was defined as a respective notification in the Unique
Person Identification registry of the Central CompensationOffice
(ZAS). Categorization of the index events and the triggering
risk factors was done according to current guidelines and
verified again in 2018 using original hospital records. As
indicators of disease severity, the type of index VTE, presence
of triggering risk factors, presence of previous VTE, and family
history were considered. Mutual exclusive groups were created
with regard to the type of index event. All patients with
PE were categorized as “Pulmonary embolism,” regardless of
concomitant thromboembolic events. Patients with DVT (lower
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FIGURE 1 | Flow of patients.
leg, upper leg, and pelvic vein thrombosis) without PE were
categorized as “Deep vein thrombosis,” regardless of additional
thromboembolic events. Patients with all other VTE, but not
PE or DVT were classified as “other VTE” (cerebral vein
thrombosis, mesenteric thrombosis, portal vein thrombosis,
upper extremity vein thrombosis, superficial vein thrombosis,
and muscle vein thrombosis). Unprovoked VTE was defined
as VTE in the absence of a reversible risk factor (surgery,
contraceptive use, pregnancy, long-distance air or car travel of
more than 10 h, immobilization, and traumatic injury at most
3 months before the VTE) (15, 16). Surgery, immobilization,
long-distance travel of more than 10 h, and traumatic injury
within 3 months before the VTE were defined as transient
risk factors. Active cancer was defined as diagnosed within the
previous 6 months, recurrent, regionally advanced or metastatic
cancer, cancer for which treatment had been administered within
6 months, or hematological cancer that is not in complete
remission (17). Pregnancy and anti-contraceptive use were
classified as hormone-related risk factors. As an indicator of
treatment intensity, the duration of anticoagulant treatment
was categorized as follows: (1) ≤6 months, (2) 7–24 months
(prolonged), (3) >24 months (permanent) (18). The smoking
status was recorded as either active smoker or non-smoker.
Patients with a BMI > 30 kg/m2 were categorized as obese.
The following comorbidities were recorded as present or absent:
arterial thrombosis, hypertension, diabetes mellitus, stroke,
coronary artery disease, kidney failure, pulmonary disease,
kidney disease, systemic diseases, and anemia.
Statistical Analysis
The baseline characteristics of the predictor variables were
presented by sex. The variables were described as numbers
(percentages) and median (interquartile range) as appropriate,
A maximum of 1.6% of the data was missing for each of the
recorded covariates and was deemed either missing at random or
missing completely at random. Therefore, we decided to impute
the missing values using an algorithm based on a random forest
approach implemented in the “missForest” package of “R.” (19).
We calculated the mortality rates per 1,000 patient-years
(py) for the whole cohort and each predictor. The accumulated
person-time at risk and the number of deaths per subgroup
were calculated. Sex and age-specific standardized mortality
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TABLE 1 | Characteristics of 6,243 patients with venous thromboembolism followed for a median of 8.13 years.
Overall Female Male Missing values
n 6,243 3,663 2,580
Median age (IQR)—y 44.60 (32.55, 56.09) 39.17 (29.36, 52.73) 49.47 (40.24, 59.28)
Index event—no. (%) 30 (0.5)
Deep vein thrombosis 2,506 (40.3) 1,526 (41.9) 980 (38.1)
Pulmonary embolism 2,679 (43.1) 1,438 (39.5) 1,241 (48.3)
Other VTE 1,028 (16.5) 680 (18.7) 348 (13.5)
Previous VTE—no. (%) 1,946 (31.2) 952 (27.2) 994 (36.4) 15 (0.2)
Family history—no. (%) 1,968 (31.6) 1,180 (32.4) 788 (30.6) 24 (0.4)
Triggering risk factors—no. (%) 30 (0.5)
Pregnancy 324 (5.2) 324 (8.8) 0 (0)
Estrogen use 1,570 (25.3) 1,570 (42.8) 0 (0)
Transient risk factors 1,697 (27.3) 764 (20.9) 933 (36.4)
Unprovoked VTE 2,622 (42.2) 992 (27.2) 1,630 (63.5)
Duration of anticoagulant treatment—no. (%) 7 (0.1)
<6 months 3,617 (58.0) 2,362 (64.5) 1,255 (48.7)
Prolonged 833 (13.4) 522 (14.3) 311 (12.1)
Permanent 1,786 (28.6) 777 (21.2) 1,009 (39.2)
Arterial thrombosis—no. (%) 285 (4.6) 124 (3.4) 161 (6.2) 0 (0.0)
Smoking—no. (%) 1,445 (23.5) 844 (23.3) 601 (23.7) 87 (1.4)
Obesity—no. (%) 1,792 (29.2) 995 (27.7) 797 (31.3) 99 (1.6)
Systemic disease—no. (%) 376 (6.0) 217 (5.9) 159 (6.2) 16 (0.3)
Diabetes mellitus—no. (%) 171 (2.7) 79 (2.2) 92 (3.6) 18 (0.3)
Coronary artery disease—no. (%) 259 (4.2) 89 (2.4) 170 (6.6) 18 (0.3)
Pulmonary disease—no. (%) 251 (4.0) 141 (3.9) 110 (4.3) 17 (0.3)
Hypertension—no. (%) 803 (12.9) 373 (10.2) 430 (16.7) 18 (0.3)
Kidney disease—no. (%) 139 (2.2) 56 (1.5) 83 (3.2) 16 (0.3)
Stroke—no. (%) 191 (3.1) 89 (2.4) 102 (4.0) 17 (0.3)
Anemia—no. (%) 217 (3.5) 160 (4.4) 57 (2.2) 17 (0.3)
Baseline demographics, measures of disease severity, treatment intensity, and comorbidities are reported by sex. IQR, interquartile range; no., number of patients; VTE,
venous thromboembolism.
ratios (SMR) were calculated by indirect standardization to
compare the mortality in the SeProV cohort with the general
Swiss population. The sex and age-specific mortality rates per
100,000 persons of the Swiss population were obtained from
the Swiss Federal Statistical Office (latest available rates from
2017). Ninety-five percent confidence intervals were calculated
using the method described by Vandenbroucke (20). The
survival curve for the whole cohort was calculated using a
Kaplan–Meier estimate. The Kaplan–Meier curves of groups
with and without risk factors were compared and a log-rank
test was employed to test the difference in cumulative hazard
between the groups. A univariate Cox proportional-hazards
model was used for each parameter. Hazard ratios (HR) and
their corresponding 95% confidence intervals were reported.
Multivariate models were created by separately entering one
of the predictors of disease severity and treatment intensity
(index event, previous VTE, family history of VTE, triggering
risk factors, and duration of anticoagulant treatment) adjusting
for age, sex, and comorbidities (arterial thrombosis, obesity,
smoking status, systemic diseases, diabetes mellitus, coronary
artery disease, pulmonary disease, hypertension, kidney disease,
stroke, and anemia). Hazard Ratios and their confidence intervals
were calculated from the coefficients. The HRs and their
respective 95% confidence intervals for age, sex, smoking status,
and comorbidities were obtained from a model including all
comorbidities but none of the predictors of disease severity and
treatment intensity.
For both the Kaplan–Meier and the Cox-Proportional-Hazard
model the assumption of non-informative censoring was tested
by comparing an optimistic model, in which all censored
times are seen as longest possible survival, to a pessimistic
model, in which all censored times are seen as deaths and
comparing them. If the results pointed in different directions,
we performed a sensitivity analysis and investigated the reasons
for informative censoring. A histogram was created plotting the
date of assessment on the x-axis and the number of patients per
vital status (alive, dead, and censored) on the y-axis. To test the
assumption of constant hazard the scaled Schoenfeld residuals
were calculated for each predictor and the correlations with time
were tested, both with a statistical test as well as visually.
Two sensitivity analyses were performed for different periods
of patient enrolment and to account for potential effects of a wide
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TABLE 2 | Long-term mortality by risk factors.
Deaths Observation period (py) Mortality rate per 1,000 py Standardized mortality ratio
Overall 254 57,212 4.44 (3.89, 4.99) 1.30 (1.14, 1.47)
Females 114 34,274 3.33 (2.72, 3.94) 1.48 (1.22, 1.77)
Males 140 23,411 5.98(4.99, 6.97) 1.18 (0.99, 1.39)
Index event
Deep vein thrombosis 91 23,908 3.81 (3.02, 4.59) 1.29 (1.04, 1.58)
Pulmonary embolism 128 24,208 5.29 (4.37, 6.20) 1.31 (1.09, 1.55)
Other VTE 35 9,569 3.66 (2.45, 4.87) 1.28 (0.88, 1.75)
Previous VTE 135 19,407 6.96 (5.78, 8.13) 1.56 (1.30, 1.84)
Family history 67 17,281 3.88 (2.95, 4.81) 1.14 (0.88, 1.44)
Triggering risk factors
Pregnancy and estrogen use 24 17,756 1.35 (0.81, 1.89) 1.27 (0.80, 1.84)
Transient risk factors 75 16,129 4.65 (3.60, 5.70) 1.27 (0.99, 1.58)
Unprovoked VTE 155 23,801 6.51 (5.49, 7.54) 1.32 (1.11, 1.54)
Duration of anticoagulant treatment
≤6 months 97 34,288 2.83 (2.27, 3.39) 1.11 (0.90, 1.35)
Prolonged 37 8,020 4.61 (3.13, 6.10) 1.49 (1.04, 2.02)
Permanent 120 15,377 7.80 (6.41, 9.20) 1.44 (1.19, 1.71)
Arterial thrombosis 19 2,483 7.65 (4.21, 11.1) 1.30 (0.77, 1.96)
Smoking 69 14,715 4.69 (3.58, 5.80) 2.57 (1.99, 3.23)
Obesity 94 16,985 5.53 (4.42, 6.65) 1.57 (1.27, 1.92)
Systemic disease 25 4,003 6.25 (3.80, 8.69) 2.05 (1.31, 2.95)
Diabetes mellitus 21 1,440 14.6 (8.35, 20.8) 2.62 (1.60, 3.89)
Coronary artery disease 29 2,183 13.3 (8.45, 18.1) 1.48 (0.98, 2.08)
Pulmonary disease 18 2,380 7.56 (4.07, 11.1) 1.53 (0.89, 2.33)
Hypertension 74 7,363 10.1 (7.76, 12.3) 1.46 (1.14, 1.82)
Kidney disease 25 1,224 20.4 (12.4, 28.4) 2.14 (1.37, 3.08)
Stroke 17 1,671 10.2 (5.34, 15.0) 1.56 (0.89, 2.40)
Anemia 18 1,959 9.19 (4.94, 13.4) 2.57 (1.50, 3.93)
Mortality rates and standardized mortality ratios are reported (Reference: Swiss general population). VTE, venous thromboembolism; py, patient-years.
range of “other VTE.” Multivariate Cox-Proportional-Hazard
models for patients enrolled between 1988–1997, 1998–2007, and
2008–2018 were fitted. Another analysis was done considering
patients with DVT and PE only. All analyses were performed
using the statistical software environment “R” (21).
RESULTS
Study Population and Patient
Characteristics
Among 15,011 patients referred between 1988 and 2018 to the
Inselspital for thromboembolic risk assessment, 6,243 patients
with objectively confirmed VTE were included in the final study
cohort after a mean 4.2 months of anticoagulation (Figure 1).
The median observation time was 8.13 years, adding up to a total
of 57,212 py. The median time between index event and VTE risk
assessment (inclusion into the study) was 1.2 years (interquartile
range [IQR]: 0.78, 1.57). The median age was 44.60 years (IQR:
32.55, 49.71) and 58.7% of the patients were female. Pulmonary
embolism was the index event in 43.1% of the patients (n =
2,679), and DVT in 40.3% (n = 2,506). Unprovoked VTE was
present in 42.2% (n= 2,622) and 31.2% (n= 1,946) had previous
VTE. Permanent anticoagulant treatment was given to 28.6%
of the patients (n = 1,786). Detailed patient characteristics are
reported in Table 1.
Mortality
Two-hundred fifty-four patients died amounting to a mortality
rate of 4.44 per 1,000 py (95% confidence interval [CI]: 3.89,
4.99). Detailed results in various subgroups are given in Table 2.
In a Kaplan Meier analysis the cumulative probability of survival
was 99.0% (95% CI: 98.7, 99.3%) after 5 years, 97.6% (95% CI:
97.0, 98.1%) after 10 years, 94.2% (95% CI: 93.3, 95.1%) after 15
years, and 89.1% (95% CI: 87.6, 90.7%) after 20 years (Figure 2).
Standardized to the Swiss general population, the SMR was 1.30
(95% CI: 1.14, 1.47). In female patients, the mortality rate was
3.33 per 1,000 py (95% CI: 2.72, 3.94; SMR: 1.48, 95% CI: 1.22,
1.77). In male patients, the mortality rate was 5.98 per 1,000 py
(95% CI: 4.99, 6.97; SMR: 1.18, 95% CI: 0.99, 1.39). The mortality
rate in patients with previous VTE was 6.96 per 1,000 py (95%
CI: 5.78, 8.13) and the SMR was 1.56 (95% CI: 1.30, 1.84). In
patients with unprovoked VTE, the mortality rate was 6.51 per
1,000 py (95%CI: 5.49, 7.54; SMR: 1.32, 95%CI: 1.11, 1.54) and in
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FIGURE 2 | Kaplan-Meier curve of survival for patients with venous thromboembolism. Two-hundred fifty-four deaths were observed in a cumulative observation
period of 57′212 patient-years (6′243 patients). The median time between index event and inclusion into the study was 1.2 years (IQR: 0.78, 1.85).
patients with pulmonary embolism as index event, the mortality
rate was 5.29 per 1,000 py (95% CI: 4.37, 6.20; SMR: 1.31, 95% CI:
1.09, 1.55). Patients with permanent anticoagulant treatment had
a mortality rate of 7.80 per 1,000 py (95% CI: 6.41, 9.20) and an
SMR of 1.44 (95% CI: 1.19, 1.71). With regard to comorbidities,
patients with coronary artery disease had a mortality rate of 13.3
per 1,000 py (95% CI: 8.45, 18.1; SMR: 1.48, 95% CI: 0.98, 2.08)
and patients with diabetes mellitus had a rate of 14.6 per 1,000 py
(95% CI: 8.35, 20.8; SMR: 2.62, 95% CI: 1.60, 3.89).
Risk Factors for Mortality
Mortality was associated with various demographic
characteristics, measures of disease severity, treatment intensity,
as well as comorbidities. In univariate analysis, the HR of male
sex was 1.87 (95% CI: 1.46, 2.40). Regarding disease severity,
the hazard ratio of previous VTE was 2.05 (95% CI: 1.60,
2.62). The HR of PE as an index event was 1.45 (95% CI: 1.10,
1.89), and the HR of unprovoked VTE was 5.06 (95% CI: 3.29,
7.77). Considering treatment intensity, the HR of prolonged
anticoagulant treatment (7–24 months) was 1.70 (95% CI: 1.16,
2.48), and the HR of permanent anticoagulant treatment was 3.14
(95% CI: 2.40, 4.12). Various cardiovascular comorbidities were
associated with an increased mortality in univariate analysis,
details are reported in Table 3 and Kaplan–Meier-Curve for
selected covariates in Supplementary Figure 1.
Adjusted for age, sex, and all comorbidities listed in Table 3,
HR previous VTE (adjusted HR: 1.33, 95% CI: 1.04, 1.71),
unprovoked VTE (adjusted HR: 1.69, 95% CI: 1.05, 2.72),
prolonged anticoagulant treatment (adjusted HR: 1.53, 95% CI:
1.04, 2.25), and permanent anticoagulant treatment (adjusted
HR: 1.66, 95% CI: 1.25, 2.21) were independent risk factors
for mortality.
The assumption of non-informative censoring was violated
as the pessimistic model for sex was not statistically
significant (HR: 0.94, 95% CI: 0.86, 1.02), whereas the
optimistic model was significant (HR: 1.93, 95% CI:
1.51, 2.47) (Supplementary Table 1). Considering the
histogram, the relative number of censored patients
remained the same until 2008, and from 2008 on decreased
(Supplementary Figure 2). The sensitivity analysis, however,
showed no significant difference when excluding the censored
patients (Supplementary Table 2). The assumption of
constant hazard, however, holds for all models created
(Supplementary Table 3; Supplementary Figure 3). No
significant differences were identified in the two sensitivity
analyses considering different periods of enrolment and patients
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TABLE 3 | Predictors of long-term mortality: Baseline demographics, measures of disease severity, treatment intensity, and comorbidities.
Univariate Multivariate*
HR 95% CI HR 95% CI
Age 1.09 1.08, 1.10 1.09 1.08, 1.11
Male Sex 1.87 1.46, 2.40 1.29 1.00, 1.65
Index event
Deep vein thrombosis – – – –
Pulmonary embolism 1.45 1.10, 1.89 1.18 0.90, 1.56
Other VTE 0.99 0.67, 1.46 0.91 0.62, 1.35
Previous VTE 2.05 1.60, 2.62 1.33 1.04, 1.71
Family history 0.86 0.65, 1.13 0.87 0.66, 1.16
Triggering risk factors
Pregnancy and estrogen use – – – –
Transient risk factors 3.46 2.18, 5.48 1.63 0.99, 2.66
Unprovoked VTE 5.06 3.29, 7.77 1.69 1.05, 2.72
Duration of anticoagulant treatment
≤6 months – – – –
Prolonged 1.70 1.16, 2.48 1.53 1.04, 2.24
Permanent 3.14 2.40, 4.12 1.66 1.25, 2.21
Arterial thrombosis 1.89 1.19, 3.02 0.76 0.39, 1.46
Smoking 0.98 0.75, 1.30 1.91 1.42, 2.57
Obesity 1.40 1.09, 1.81 1.15 0.88, 1.50
Systemic disease 1.32 0.88, 2.00 1.07 0.70, 1.63
Diabetes mellitus 4.01 2.56, 6.29 2.09 1.31, 3.32
Coronary artery disease 3.92 2.66, 5.78 1.56 1.03, 2.37
Pulmonary disease 1.88 1.16, 3.03 1.38 0.85, 2.24
Hypertension 3.01 2.29, 3.94 1.19 0.89, 1.59
Kidney disease 5.58 3.69, 8.44 2.31 1.47, 3.63
Stroke 2.51 1.53. 4.11 1.38 0.69, 2.76
Anemia 2.23 1.38, 3.60 2.34 1.42, 3.87
VTE, venous thromboembolism; HR, hazard ratio; CI, confidence interval.
*Adjusted by age, sex, and comorbidities.
with DVT and PE only (Supplementary Tables 4, 5). However,
the models fitted to different enrolment times became unstable
due to small sample sizes (particularly with regard to the time
period 1988 to 1997).
DISCUSSION
We conducted a large, prospective cohort study, recording
a broad set of predictor variables, and following for up
to 30 years, to comprehensively assess the effect of disease
severity, treatment intensity, and comorbidities on the long-
term survival of patients with VTE. Two-hundred and fifty-
four deaths were observed among 6,243 patients over an
observation period of 57,212 patient-years. Compared to
the general Swiss population, long-term mortality of VTE
patients was increased by 30%. Besides higher age and
male sex, increased mortality was associated with measures
of disease severity, treatment intensity, and cardiovascular
comorbidities. Previous VTE, unprovoked VTE, prolonged,
and permanent anticoagulant treatment were independent risk
factors for mortality.
Even though a less strict study design was used in most
publications, some aspects were observed previously. Increased
mortality was found by two large case-control studies and one
retrospective cohort study (6, 12, 22), but not in a smaller
study conducted in young women comparing the mortality
rate with the general population (23). Older age and male sex
were identified as a risk factor in the SWITCO65+ cohort
(8), in the Olmsted county cohort (7), and in the Taiwanese
National Health Insurance study (12). Diabetes mellitus and
other cardiovascular risk factors and comorbidities were reported
in an analysis of the Taiwanese National Health Insurance
database (12), the SWITCO65+ cohort (8), and the Olmsted
county cohort (7). As a measure of disease severity, unprovoked
VTE was observed as a risk factor in the TEHS cohort (13),
and in a Norwegian cohort (14). As additional disease severity
measures, we found PE as index event, previous VTE, and
transient triggering factors to be risk factors for mortality.
One previous study analyzed long-term heparin-treatment as a
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measure of treatment intensity (11), which was associated with
mortality. In our study, prolonged and permanent anticoagulant
treatment were associated with increased mortality (HR: 1.53
and 1.66, respectively). To explore causal relations, we also
adjusted disease severity measures and treatment intensity for
age, sex, and cardiovascular comorbidities, leaving prolonged and
permanent anticoagulant treatment as an independent predictor
of mortality.
Our study has several strengths. We included a large
number of patients and followed them prospectively for up
to 30 years. We recorded a broad set of predictor variables
reflecting measures of disease severity, treatment intensity, and
comorbidities. The quality of the data is high, and the percentage
of missing values is low.
As with every study, methodological limitations and potential
sources of bias appear. First, selection bias is a potential source of
bias in this study. A heterogeneous group of general practitioners
and specialists referred the patients, and unconscious influences
may have affected referral decisions. In our cohort, the patients
were relatively young (mean 44.6 years) and the proportion
of individuals with pregnancy or estrogen-associated VTE was
relatively high (30.5%). Thus, the results might differ in an
older population, which must be clarified in future studies.
Secondly, data on whether the general practitioner prescribed
vitamin K antagonists or direct oral anticoagulants (DOAC)
following the risk assessment are unavailable. This selection
might have affected the results since DOAC were increasingly
used since 2012. Even though a sensitivity analysis by time
period did not find relevant differences, we cannot fully exclude
that this might have influenced the results. Thirdly, clinical
data were collected during the routine assessment by a trained
physician using a standardized questionnaire. However, some
questions, e.g., smoking habits, rely on self-reported answers,
and are, therefore, prone to information bias. Fourthly, clinical
data collection was continued until 2018 and the time points
of death were obtained in 2019. Therefore, patients who were
assessed early in the study have a much longer follow-up
time than patients who were assessed more recently. Therefore,
there might be an underestimation of associations of predictors
that are more common now than 20 years ago. Fifthly, the
assumption of uninformative censoring did not hold. The most
likely explanation for this is the change of the SV number in
Switzerland in 2008. However, we assume that the censoring
before 2008 is random and the sensitivity analysis did not show a
significant change in the effect of the predictors.
Our results confirm previous data that the long-term survival
of patients with VTE is reduced. Patients with more severe
disease and more intense treatment are at higher risk of
death. This effect can be partially explained by cardiovascular
comorbidities, suggesting an association between both clinical
situations. However, more severe disease and more intense
treatment remain independent risk factors for mortality.
Close monitoring and reduced-intensity treatment schemes are
potential targets to improve long-term care in patients with
severe VTE. Reduced dosages of direct oral anticoagulants
might fill this gap. Future studies shall verify our results
in different settings and investigate the potential benefits of
reduced-intensity treatment schemes in patients that require
permanent anticoagulant treatment.
In a large, prospective cohort study, recording a broad set
of predictor variables, and following patients for up to 30
years, we comprehensively assessed the effect of disease severity,
treatment intensity, and comorbidities on the long-term survival
of patients with VTE. Our data indicate that the long-term
survival of patients with VTE is indeed restricted. Survival after
VTE was significantly reduced in patients with more severe
disease, cardiovascular comorbidities, and longer anticoagulant
treatment. Our results need to be verified in other settings and
populations, especially older patients.
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